InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,463.40
(
-0.18%
)
US TECH 100
19,238.00
(
-0.11%
)
Dow Jones
39,135.36
(
0.00%
)
Brent Oil
84.45
(
-0.66%
)
Bitcoin
63,534.92
(
-1.98%
)
Post# of 252290
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Titan V

Send PM Follow Ignore
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Titan V

Re: Titan V post# 215102

Wednesday, 11/15/2017 9:28:25 AM

Wednesday, November 15, 2017 9:28:25 AM

Post# of 252290
Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors
http://www.businesswire.com/news/home/20171115005760/en/Moderna-Announces-First-in-Human-Dosing-Phase-1-Study

--Novel cancer vaccine encodes 20 neoepitopes on a single mRNA molecule to elicit a completely individualized immune response--

--Moderna and Merck collaborating to evaluate mRNA-4157 in combination with KEYTRUDA® (pembrolizumab)

———

This $5 Billion Startup Made Its First Cancer Vaccine—For Just One Person
https://www.bloomberg.com/news/features/2017-11-15/this-5-billion-startup-made-its-first-cancer-vaccine-for-just-one-person


Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up